‫)‪Health Insurance Organization (HIO‬‬ ‫اﻟﻬﯿﺌﺔ اﻟﻌﺎﻣﺔ ﻠﺘ ٔﻣﲔ اﻟﺼﺤﻲ‬

‫)‪Nasr City Cancer Center (NCCC‬‬ ‫ﻣﺮﻛﺰ ٔورام ﻣﺪﯾﻨﺔ ﻧﴫ‬

‫‪Drug Information and Outcomes Research Center‬‬ ‫ﻣﺮﻛﺰ ﻣﻌﻠﻮﻣﺎت ا&واء وا‪$‬ﺮ‪#‬ﺎت اﻟﺒﺤﺜﯿﺔ‬

‫ﻟﻘﺴﻢ اﻟﺘﻤ ﻦ اﻟﻄ واﻟﺼ ﺪﻟ ﺎت‬ ‫اﻟﻬ ﻞ اﻟﺘﻨﻈ‬

‫ﻟﻠﺗﻣﻭﻳﻥ ﺍﻟﻁﺑﻲ ﻭﺍﻟﺻﻳﺩﻟﻳﺎﺕ‬

‫ﻭﺣﺩﺓ ﺗﺣﺿﻳﺭ‬ ‫ﻗﺳﻡ ﺍﻟﻣﻌﻠﻭﻣﺎﺕ‬ ‫ﺍﻟﺻﻳﺩﻟﺔ‬ ‫ﻣﺭﺍﻗﺑﺔ ﺍﻟﻌﻬﺩ‬

‫ﺍﻟﺻﻳﺩﻟﻳﺎﺕ‬ ‫ﺍﻟﻣﺧﺎﺯﻥ ﺍﻟﻁﺑﻳﺔ‬ ‫ﺗﻣﻭﻳﻥ ﻁﺑﻲ‬
‫ﺍﻟﻌﻼﺝ ﺍﻟﻛﻳﻣﺎﻭﻱ‬ ‫ﺍﻟﺩﻭﺍﺋﻳﺔ‬ ‫ﺍﻹﻛﻠﻳﻧﻛﻳﺔ‬ ‫)ﺍﻟﺷﻁﺏ(‬

‫ﻣﺭﻛﺯ ﻣﻌﻠﻭﻣﺎﺕ‬
‫ﺻﻳﺩﻟﻳﺔ ﺍﻟﻛﻳﻣﺎﻭﻱ‬ ‫ﺍﻟﻣﺧﺯﻥ ﺍﻟﺭﺋﻳﺳﻲ‬ ‫ﺷﻁﺏ ﺍﻟﻣﺧﺎﺯﻥ‬ ‫ﺍﻟﺗﻭﺭﻳﺩﺍﺕ‬
‫ﺍﻟﺩﻭﺍء‬

‫ﻭﺣﺩﺓ ﺍﻟﻳﻘﻅﺔ‬ ‫ﻣﺧﺯﻥ ﺍﻟﻣﻌﺎﻣﻝ‬

‫ﺻﻳﺩﻟﻳﺔ ﺍﻟﺩﺍﺧﻠﻲ‬ ‫ﺷﻁﺏ ﺍﻟﺻﻳﺩﻟﻳﺎﺕ‬ ‫ﺍﻟﺣﺳﺎﺑﺎﺕ‬
‫ﺍﻟﺩﻭﺍﺋﻳﺔ‬ ‫ﻭﺍﻟﻣﺳﺗﻠﺯﻣﺎﺕ‬

‫ﻭﺣﺩﺓ ﺍﻗﺗﺻﺎﺩﻳﺎﺕ‬ ‫ﺻﻳﺩﻟﻳﺔ‬

‫ﻣﺧﺯﻥ ﺍﻟﻌﻣﻠﻳﺎﺕ‬
‫ﺍﻟﺩﻭﺍء‬ ‫ﺍﻟﻣﺳﺗﻠﺯﻣﺎﺕ‬

‫ﺻﻳﺩﻟﻳﺔ‬ ‫ﻣﺧﺯﻥ ﺍﻻﺟﻬﺯﺓ‬

‫ﺍﻟﻣﺧﺩﺭﺍﺕ‬ ‫ﺍﻟﻁﺑﻳﺔ‬

‫اﻟﻮﺿﻊ اﻟﺤﺎ‬
‫ا‪+‬ﺸﺎء ﻣﺮﻛﺰ ﻣﻌﻠﻮﻣﺎت اﻟﺪواء واﻟﻤﺨﺮﺟﺎت اﻟ‪1‬ﺤﺜ ﺔ ﻃ‪1‬ﻘﺎ ﻟﻘﺮار وز ﺮ اﻟﺼﺤﺔ رﻗﻢ )‪ (٣٩١‬ﻟﺴﻨﺔ ‪ ٢٠١٢‬ووﺿﻊ‬ ‫‪.١‬‬
‫اﻟﻬ ﻞ واﻟﺘﻮﺻ ﻒ اﻟﻮﻇ ;< ﻃ‪1‬ﻘﺎ ﻟﻤ‪G‬ﺸﻮرات اﻹدارة اﻟﻤﺮﻛ‪ D‬ﺔ ﻟﻠﺸﺌﻮن اﻟﺼ ﺪﻟ ﺔ ﺑﻮزارة اﻟﺼﺤﺔ واﻟﺴ ﺎن‪.‬‬
‫;‬ ‫‪S‬‬ ‫‪.٢‬‬
‫ﻟﻠﻤﻌﺎﻳ‪ I‬اﻟﻌﺎﻟﻤ ﺔ )‪(USP 797 & USP 800‬‬
‫‪H‬‬ ‫ﺗﺤﻀ‪ I‬اﻟ‪ L‬ﻤﺎوي ﻃ‪1‬ﻘﺎ‬‫‪H‬‬ ‫ﻣﻌﺎﻳ‪ I‬ﺗﺼﻤ ﻢ ﻏﺮﻓﺔ‬
‫‪H‬‬ ‫اﻹﺷ‪I‬اك ‪ Q‬وﺿﻊ‬
‫ا‪+‬ﺸﺎء ﻟﺠﻨﺔ اﻟﺪواء واﻟﻌﻼﺟ ﺎت )‪ ( Therapeutic & Medication Committee‬وﺗﺤﺪ‪r‬ﺪ أﻋﻀﺎءﻫﺎ وﻣﻬﺎﻣﻬﺎ‬ ‫‪.٣‬‬
‫ﻟﻠﻤﻌﺎﻳ‪ I‬اﻟﻤﺤﻠ ﺔ واﻟﺪوﻟ ﺔ وﺗﺤﺪ‪r‬ﺪ ﻣﻮﻋﺪ وﻣ ﺎن اﻧﻘﺎدﻫﺎ ‪t‬ﺼﻔﺔ دور ﺔ‪.‬‬
‫‪H‬‬ ‫ﻃ‪1‬ﻘﺎ‬
‫‪S‬‬
‫اﺳﺘﺤﺪاث ﻟﺠﻨﺔ ﻟ‪I‬ﺷ ﺪ اﺳﺘﺨﺪام اﻟﻤﻀﺎدات اﻟﺤﻴ ﺔ )‪(Antimicrobial stewardship Committee‬‬ ‫‪.٤‬‬
‫‪ .٥‬ﺗﺼﻤ ﻢ ‪ clinical pharmacy sheet‬ﻟﺘﻔﻌ ﻞ دور اﻟﺼ ﺪﻟﺔ اﻻ‪ƒ‬ﻠﻴﻨﻜ ﺔ ‪t‬ﺎﻟﻤﺮﻛﺰ‪.‬‬
‫اﻻﺷ‪I‬اك ;‪ Q‬ﺗﺼﻤ ﻢ اﻟﻤﻠﻒ اﻟﻄ ﻣﻊ ﻗﺴﻢ اﻟﺠﻮدة ‪.‬‬
‫‪S‬‬ ‫‪.٦‬‬
‫;‬ ‫‪S‬‬ ‫;‬
‫‪ .٧‬اﻟﻤﺸﺎرﻛﺔ ‪ Q‬ﺗﺼﻤ ﻢ اﻟﻤﻠﻒ اﻟﻄ اﻹﻟ‪IL‬و‪t Š‬ﺎﻟﻤﺮﻛﺰ ووﺿﻊ اﻟﺘﺼﻮر ﻟﻪ ﻣﻊ ‡‬
‫اﻟˆﻛﺔ اﻟﻤﻮردة ﻟﻠﺴ‹ﺘ ﻢ‪.‬‬

‫‪1‬‬
 ‫)‪Health Insurance Organization (HIO‬‬ ‫اﻟﻬﯿﺌﺔ اﻟﻌﺎﻣﺔ ﻠﺘ ٔﻣﲔ اﻟﺼﺤﻲ‬
‫)‪Nasr City Cancer Center (NCCC‬‬ ‫ﻣﺮﻛﺰ ٔورام ﻣﺪﯾﻨﺔ ﻧﴫ‬
‫‪Drug Information and Outcomes Research Center‬‬ ‫ﻣﺮﻛﺰ ﻣﻌﻠﻮﻣﺎت ا&واء وا‪$‬ﺮ‪#‬ﺎت اﻟﺒﺤﺜﯿﺔ‬

‫ﻣﻌﺎﻳ‪ I‬اﻟﺠﻤﻌ ﺔ اﻹﻣ‘ ﻜ ﺔ ﻟﺼ ﺎدﻟﺔ اﻟﻨﻈﺎم اﻟﺼ“‬

‫‪H‬‬ ‫‪ .٨‬ﺗﺼﻤ ﻢ ‪ Drug Formulary‬ﻷدو ﺔ اﻟ‪ L‬ﻤﺎوي ﺑﻨﺎء ﻋ’‬
‫‪ .٩‬ﺗﺼﻤ ﻢ ﻗﺎﺋﻤﺔ اﻷدو ﺔ اﻷﺳﺎﺳ ﺔ )‪ (Essential Drug List‬اﻟﻤﺘﻮاﺟﺪة ‪t‬ﺎﻟﻤﺮﻛﺰ ‪.‬‬
‫‪ .١٠‬ﺗﺼﻤ ﻢ ‪I.V sequencing charts & I.V Incompatibly chart & Newsletter & Patient flyers‬‬
‫)‪. Compounding guidelines & & Drug Information requests (DIRs‬‬
‫ﻣﺤﺎ‪Ÿ‬ات ﻟﻠﻔ‘ ﻖ اﻟﻄ ﻣﻦ اﻻﻃ‪1‬ﺎء واﻟﺼ ﺎدﻟﺔ واﻟﺘﻤ‘ ﺾ ﻟﺮﻓﻊ اﻟﻤﺴﺘﻮي اﻟﻌﻠ واﻻﻃﻼع ﻋ’ ﻣﺎ‬ ‫;‬ ‫‪ .١١‬ﺗﻨﻈ ﻢ‬
‫;‬
‫¡ﺴﺘﺠﺪ ‪ Q‬ﻋﻼﺟ ﺎت اﻷورام‬
‫;‬
‫‪ .١٢‬اﻟﻘ ﺎم ‪t‬ﻤﺠﻤﻮﻋﺔ ﻣﻦ اﻟﺪارﺳﺎت ﻻﻹﻗﺘﺼﺎد‪r‬ﺔ واﻟ ‪¢‬ﺎﺋ ﺔ ‪ Q‬ﺗﻘﻴ ﻢ ‪-:‬‬
‫‪ Q; Vectibix® & Erbitux® ‬ﻋﻼج ‪ ) MCR cancer‬ﺗﻮﻓ ‪ ٤٠ IH‬اﻟﻒ ﺟﻨﻴﻬﺎ ﺷﻬ‘ ﺎ ‪/‬ﻟﻠﻤ‘ ﺾ( ‪.‬‬
‫;‬
‫‪ ‬اﻷﻗﺮاص اﻟﻤﻀﺎدة ﻟﻠﻘ ‪t © H‬ﺪﻻ ﻣﻦ اﻷﻣﺒﻮﻻت ‪ Q‬ﺣﺎﻻت ﻣﺤﺪدة ﻛﺠﺰء ﻣﻦ اﻟﻌﻼج اﻟﺘ ﻤ ’ ﻟﻠﻌﻼج اﻟ‪ L‬ﻤﺎوي ‪.‬‬
‫;‬
‫‪t‬ﺎﻟﻤﺴ®ﺸ< ‪.inpatient infusion‬‬ ‫;‬
‫‪ ‬اﻟﻤﻀﺨﺔ ‪ Q‬إﻋﻄﺎء دواء ‪t fluorouracil‬ﺎﻟﻤﻘﺎرﻧﺔ ﻣﻊ اﻹﻗﺎﻣﺔ‬
‫ﺗﻮﻓ‪ ٢ I‬ﻣﻠﻴﻮن ﺟﻨ ﺔ ﺳﻨ ﺎ (‬‫‪H ) Subcut. Versus I.V Trastuzumab in HRE-2 +ve Breast Cancer ‬‬
‫‪ ‬ﺣﺴﺎب ﺗﻘﺪﻳﺮي ﻟﺘ ﻠﻔﺔ ﻋﻼج ﻣ‘ ﺾ أورام اﻟﺜﺪي‪.‬‬
‫;‬
‫ﻟﻤﺮ¶ اﻷورام‬ ‫‪ ‬ﺗﺤﺪ‪r‬ﺪ اﻟﻤﺨﺎﻃﺮ اﻟ ‪ S‬ﺗﺆدي ا اﻟﺘﻔﺎﻋﻼت اﻟﻌﻜﺴ ﺔ ‪t‬ﻜﺮات اﻟﺪم اﻟﺒ ﻀﺎء واﻟﺼﻔﺎﺋﺢ اﻟﺪﻣ ﺔ‬
‫ﻧ® ﺠﺔ اﺳﺘﺨﺪام دواء ‪ carboplatin‬وارﺳﺎل اﻟﺘﻮﺻ ﺎت ا اﻟﻬﻴﺌﺔ ‪.‬‬
‫‪; S‬‬ ‫;‬
‫اﻟ‪IL‬و‪ Š‬ﻟ®ﺴﺠ ﻞ ﺣﺎﻻت اﻷورام )‪(Cancer Registry‬‬ ‫‪ .١٣‬اﻟﻤﺸﺎرﻛﺔ ‪ Q‬وﺿﻊ ﺗﺼﻮر ﻟﺘﺼﻤ ﻢ ﺑﺮﻧﺎﻣﺞ‬
‫‪; H‬‬
‫ﻻﻟﺒﻴﻮﻣ¼ ﻃ‪1‬ﻘﺎ ﻟﻠ‪I‬ﺗﻜﻮﻻت واﻟﺘﻮﺻ ﺎت اﻟﺪواﺋ ﺔ اﻟﻌﺎﻟﻤ ﺔ‪.‬‬ ‫‪ .١٤‬ﺗﺼﻤ ﻢ ﺑﺮﺗﻜﻮل ﻋﻼ» ‪S‬ﻟ‪I‬ﺷ ﺪ اﺳﺘﺨﺪام ا‬
‫‪ .١٥‬ﺣﻀﻮر ‪t‬ﻌﺾ اﻟﻤﺆﺗﻤﺮات و اﻟﺘﺪر ﺐ اﻟﺪو واﻟﺘﻮاﺻﻞ ﻣﻊ اﻟﻤﺆﺳﺴﺎت اﻟﻌﻠﻤ ﺔ اﻟﺪوﻟ ﺔ ﻣﺜﻞ )‪ (EMPHNET‬و‬
‫ﻣ‪I‬ﻻﻧﺪ ‪t‬ﺎﻟﻮﻻ‪r‬ﺎت اﻟﻤﺘﺤﺪة اﻷﻣ‘ ﻜ ﺔ‪.‬‬
‫)‪ (ISPOR‬و )‪)(FIP‬اﺗﺤﺎد اﻟﺼ ﺎدﻟﺔ اﻟﺪو ( و ¿ﻠ ﺔ اﻟﻄﺐ ‪-‬ﺟﺎﻣﻌﺔ ‪H‬‬
‫‪ .١٦‬ﻓﺼﻞ ﺻ ﺪﻟ ﺔ اﻟﺪاﺧ’ ﻋﻦ ﺻ ﺪﻟ ﺔ اﻟ‪ L‬ﻤﺎوي‪.‬‬
‫ﻟﻠﻤﺨﺎزن اﻟﻄﺒ ﺔ‪.‬‬ ‫‪ .١٧‬ﺗﺤﺪ‪r‬ﺚ اﻟﻬ ﻞ اﻟﺘﻨﻈ‬
‫‪ .١٨‬اﺳﺘﺤﺪاث ﺻ ﺪﻟ ﺔ اﻟﻤﺴﺘﻠﺰﻣﺎت اﻟﻄﺒ ﺔ ‪t‬ﺎﻟﻤﺮﻛﺰ ‪.‬‬
‫;‬
‫ﻟﻤﺮ¶ اﻷورام‪.‬‬ ‫‪ .١٩‬ا‪+‬ﺸﺎء و‪Â‬ﻓﺘﺘﺎح ﻋ ﺎدة اﻟﺘﻐﺬ‪r‬ﺔ‬
‫اﻟﻌﻼج اﻹﺷﻌﺎ‪ Æ‬واﻟﻄﺐ اﻟﻨﻮوي واﺳﺘﻼم اﻷﺟﻬﺰة اﻟﻄﺒ ﺔ‬ ‫‪H .٢٠‬‬
‫ﺗﻮﻓ‪ I‬ﺟﻤﻴﻊ اﻟﻤﺴﺘﻠﺰﻣﺎت اﻟﻄﺒ ﺔ واﻹﺷﻌﺎﻋ ﺔ ﻟﻘﺴ‬
‫ﻟﻬﺬە اﻷﻗﺴﺎم ‪t‬ﻌﺪ ﺗﺨ‪ È‬ﺟﻤﻴﻊ اﻟﻌﺮاﻗ ﻞ اﻹدار ﺔ واﻟﻔﻨ ﺔ ﻹﺗﻤﺎم و‪É‬ﺸﻐ ﻞ ﻫﺬە اﻻﻗﺴﺎم ‪t‬ﺎﻟﻤﺮﻛﺰ ﻟﺨﺪﻣﺔ اﻟﻤ‘ ﺾ‬
‫ﻟﻤﻌﺎﻳ‪ I‬وزارة اﻟﺼﺤﺔ ‪.‬‬
‫‪H‬‬ ‫ﻓ‪ I‬ﺟﻤﻴﻊ اﻟﻤﺴﺘﻠﺰﻣﺎت اﻟﻄﺒ ﺔ اﻟﻮﻗﺎﺋ ﺔ وذﻟﻚ ﻟﻤﺠﺎﺑﻬﺔ ﺟﺎﺋﺤﺔ ‪ covid-19‬ﻃ‪1‬ﻘﺎ‬ ‫‪ .٢١‬ﺗﻮ ‪H‬‬
‫;‬ ‫;‬
‫ﻣﺤﺎ‪Ÿ‬ات وﺣﻀﻮر دورات ﺗﺪر ‪ Í‬ﺔ ‪¿ Q‬ﻼ ﻣﻦ ‪-:‬‬ ‫‪ .٢٢‬ﺗﻨﻈ ﻢ‬
‫‪ ‬ﻧﻈﺎم ‡‬
‫اﻟˆاء اﻟﻤﻮﺣﺪ وﻧﻈﺎم اﻹﻣﺪاد اﻟﻄ‬
‫‪ ‬اﻹﺣﺼﺎء اﻟﻄ ‪.‬‬
‫ﻟﻤﻌﺎﻳ‪ I‬ﻣﻨﻈﻤﺔ اﻟﺼﺤﺔ اﻟﻌﺎﻟﻤ ﺔ ‪.‬‬
‫‪H‬‬ ‫‪ ‬اﻟﻤﻀﺎدات اﻟﺤﻴ ﺔ وﺗﺮﺷ ﺪ اﺳﺘﺨﺪاﻣﻬﺎ ﻃ‪1‬ﻘﺎ‬

‫‪2‬‬
 Health Insurance Organization (HIO) ‫اﻟﻬﯿﺌﺔ اﻟﻌﺎﻣﺔ ﻠﺘ ٔﻣﲔ اﻟﺼﺤﻲ‬
Nasr City Cancer Center (NCCC) ‫ﻣﺮﻛﺰ ٔورام ﻣﺪﯾﻨﺔ ﻧﴫ‬
Drug Information and Outcomes Research Center ‫ﺎت اﻟﺒﺤﺜﯿﺔ‬#‫ﺮ‬$‫ﻣﺮﻛﺰ ﻣﻌﻠﻮﻣﺎت ا&واء وا‬

Our Vision
To be the National Role Model in Oncology Pharmacy in Egypt.

Our Mission
Advancing healthcare for oncology patients as accountable members of the patient
care team
 Optimizing patient outcomes through interdisciplinary medication management.
 Lifelong learning through education of patients, students, residents and others.
 Outcomes & Health Service Research to enhance the quality and safety of
healthcare.

Our Values
Accountability
Ensuring the best medication use outcomes, putting patients and families first.

Excellence
Demonstrating excellence in all that we do.

Integrity
Using resources wisely and building trust.

Innovation
Transforming the way pharmacy care is delivered with an entrepreneurial spirit.

Respect

Creating an inclusive and compassionate environment for people of all backgrounds

3
 Health Insurance Organization (HIO) ‫اﻟﻬﯿﺌﺔ اﻟﻌﺎﻣﺔ ﻠﺘ ٔﻣﲔ اﻟﺼﺤﻲ‬
Nasr City Cancer Center (NCCC) ‫ﻣﺮﻛﺰ ٔورام ﻣﺪﯾﻨﺔ ﻧﴫ‬
Drug Information and Outcomes Research Center ‫ﺎت اﻟﺒﺤﺜﯿﺔ‬#‫ﺮ‬$‫ﻣﺮﻛﺰ ﻣﻌﻠﻮﻣﺎت ا&واء وا‬

Future Plan 2020-2021

Goal #1 Updating i.v Chemotherapy compounding procedures & I.V compatibility & I.V se-
quencing charts
Goal #2 Updating Drug formulary and essential drug list.
Goal #3 Updating Chemotherapy protocols.
Goal #4 Using and implementing Automated Drug Store and Health Information System.
Goal #5 Conducting Pharmacoeconomic evaluations of chemotherapy protocols.
Goal #6 Accredited as training center for Clinical Pharmacy Fellowship program.
Goal #7 Opening outpatient Oncology Pharmacy.
Goal #8 Implementing Basic and advanced training programs for Pharmacists.
Goal #9 Re-structuring Medical supply in accordance to regulations of Unified Purchasing
Authority and Egyptian Drug Authority.

Strategic Plan (2020-2025)